Biomarker solutions to accelerate global clinical trials

Molecular Insights— base by base, from target discovery to commercial launch.

We are applying our expertise in genomic profiling to identify elusive cancer-related genetic changes and new biomarker targets across many cancer types. Our advanced cancer genome analysis helps researchers and biopharmaceutical partners accelerate new precision medicine development.

Comprehensive support for biomarker-driven drug development

We support genomic profiling of Phase I-III clinical trial samples in our CLIA-certified and CAP-accredited laboratories utilizing our panel of comprehensive molecular profiling assays.


Liquid biopsy for treatment selection, disease monitoring, and MRD detection

Molecular profiling

One panel does not fit all

We offer a portfolio of comprehensive genomic profiling assays for precision medicine development.

Immuno-oncology and biomarker solutions

  • TMB
  • MSI
  • PDL1 (CNV, SV)

DNA damage repair and clinical solutions

  • BRCA1/2
  • ATM
  • FGFR1/2/3/4

Fusion and splicing RNA solutions

  • NTRK1/2/3
  • AR
  • MET


Harmonized assay with unified workflow in U.S. and China for cross-border trials

We provide harmonized assays supported by unified quality management systems and workflow in our network of CLIA-certified and CAP-accredited facilities in U.S. and China to support cross-border clinical studies.

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.